Bristol-Myers Squibb and Transgene have closed a new clinical research collaboration to evaluate the safety, tolerability and efficacy of Transgene’s investigational therapeutic vaccine TG4010 in combination with BMS’s nivolumab and standard chemotherapy as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) in patients whose tumors have low or undetectable levels of PD-L1. The phase 2 trial will evaluate objective tumor responses, and disease control in patients whose tumors express low and undetectable levels of PD-L1.